Perceived Impact on the Daily Lives of Patients With Spinal Muscular Atrophy Treated With Nusinersen
- 10 March 2026
- journal article
- research article
- Published by Wolters Kluwer Health in American Journal of Physical Medicine & Rehabilitation
- Vol. 105 (7) , 597-602
Abstract
Objective: Spinal muscular atrophy (SMA) is a rare neuromuscular disorder caused by SMN1 mutations, leading to progressive muscle weakness. Although nusinersen improves motor function, its broader impact on daily life remains insufficiently understood. This study explored caregivers’ perceptions of nusinersen treatment and identified themes reflecting its influence on everyday functioning. Methods: An observational study included 23 children with SMA (10 type 2, 7 type 3, 6 type 1) treated with nusinersen for up to 36 months. The mean age at interview was 6.3 years (SD: 2.3). Caregivers completed a semistructured questionnaire with closed and open-ended items. Narrative responses were analyzed using natural language processing (NLP) and topic modeling to identify recurring patterns. Results: Caregivers reported consistent positive effects. NLP identified 3 thematic clusters: functional and daily progress (34.9%), global improvement and quality of life (33.6%), and hospitalization and physical recovery (31.5%). Reported benefits included improved swallowing, easier breathing, fewer hospitalizations, increased independence, and enhanced mood. Families emphasized reduced stress and improved family dynamics. Conclusions: Caregivers perceive nusinersen as providing meaningful improvements in daily functioning beyond motor outcomes. Incorporating caregiver-reported insights through NLP may enrich treatment evaluation and support holistic, patient-centered and family-centered care in SMA.Keywords
This publication has 26 references indexed in Scilit:
- Systematic Review and Meta-analysis of Long-Term Nusinersen Effectiveness in Adolescents and Adults with Spinal Muscular AtrophyAdvances in Therapy, 2025
- Natural language processing with machine learning methods to analyze unstructured patient-reported outcomes derived from electronic health records: A systematic reviewArtificial Intelligence in Medicine, 2023
- Impact of nusinersen on the health‐related quality of life and caregiver burden of patients with spinal muscular atrophy with symptom onset after age 6 monthsMuscle & Nerve, 2023
- Caregiver Burden of Spinal Muscular Atrophy: A Systematic ReviewPharmacoEconomics, 2022
- Nusinersen efficacy data for 24‐month in type 2 and 3 spinal muscular atrophyAnnals of Clinical and Translational Neurology, 2022
- Nusinersen treatment in adults with severe spinal muscular atrophy: A real-life retrospective observational cohort studyRevue Neurologique, 2022
- Quality of life assessment in adult spinal muscular atrophy patients treated with nusinersenJournal of Neurology, 2022
- Nusinersen: A Review in 5q Spinal Muscular AtrophyCNS Drugs, 2021
- A multi-source approach to determine SMA incidence and research ready populationJournal of Neurology, 2017
- Evaluating topic model interpretability from a primary care physician perspectiveComputer Methods and Programs in Biomedicine, 2015